Last reviewed 2026-04-19 · How we verify

MEDI-551 300 MG-SC

MedImmune LLC · Phase 1 active Small molecule

MEDI-551 300 MG-SC is a Small molecule drug developed by MedImmune LLC. It is currently in Phase 1 development.

At a glance

Generic name	MEDI-551 300 MG-SC
Sponsor	MedImmune LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MEDI-551 300 MG-SC CI brief — competitive landscape report
MEDI-551 300 MG-SC updates RSS · CI watch RSS
MedImmune LLC portfolio CI

Frequently asked questions about MEDI-551 300 MG-SC

What is MEDI-551 300 MG-SC?

MEDI-551 300 MG-SC is a Small molecule drug developed by MedImmune LLC.

Who makes MEDI-551 300 MG-SC?

MEDI-551 300 MG-SC is developed by MedImmune LLC (see full MedImmune LLC pipeline at /company/medimmune-llc).

What development phase is MEDI-551 300 MG-SC in?

MEDI-551 300 MG-SC is in Phase 1.

Manufacturer: MedImmune LLC — full pipeline
Compare: MEDI-551 300 MG-SC vs similar drugs
Pricing: MEDI-551 300 MG-SC cost, discount & access